Data as of May 17
| -0.01 / -12.50%|
Myrexis, Inc. is a biopharmaceutical company. It focuses on identifying, evaluating and acquiring commercial-stage biopharmaceutical assets. The company has a pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis's oncology programs currently have two active programs: Hsp90 Inhibitor Program and Cancer Metabolism Inhibitor Program. The Hsp90 Inhibitor Program is an MPC-3100, a phase I clinical trial product candidate for cancer treatment. The Cancer Metabolism Inhibitor Program is an MPC-8640, a preclinical compound for the Cancer Metabolism Inhibitor program and is being developed by Myrexis as a drug candidate for the treatment of a variety of cancers. Myrexis was founded in January 2009 and is headquartered in Salt Lake City, UT.
|Jonathan Couchman||Chairman, President & Chief Executive Officer|
|Andrea E. Kendell||Chief Financial Officer, Secretary & Treasurer|
|Andrew Beelen||Vice President-Clinical Research|
|Kenton H. Zavitz, PhD||Senior Director-Clinical Affairs|
|Gradon D. Knotts, MBA||Vice President-Business Development|